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Abstract: The annotation of small molecules remains a major challenge in untargeted mass
spectrometry-based metabolomics. We here critically discuss structured elucidation approaches
and software that are designed to help during the annotation of unknown compounds.
Only by elucidating unknown metabolites first is it possible to biologically interpret complex
systems, to map compounds to pathways and to create reliable predictive metabolic models for
translational and clinical research. These strategies include the construction and quality of tandem
mass spectral databases such as the coalition of MassBank repositories and investigations of MS/MS
matching confidence. We present in silico fragmentation tools such as MS-FINDER, CFM-ID, MetFrag,
ChemDistiller and CSI:FingerID that can annotate compounds from existing structure databases and
that have been used in the CASMI (critical assessment of small molecule identification) contests.
Furthermore, the use of retention time models from liquid chromatography and the utility of collision
cross-section modelling from ion mobility experiments are covered. Workflows and published
examples of successfully annotated unknown compounds are included.
Keywords: tandem mass spectrometry; library search; in silico fragmentation; high resolution mass
spectrometry; compound identification; metabolomics
1. Introduction
Metabolomics is the comprehensive study of small molecules present in cells, tissues and body
fluids. Advances in metabolic profiling have led to discoveries of biomarkers in a variety of medical
conditions using metabolomics and lipidomics approaches, including the vision to utilize metabolomics
for precision medicine [1–3]. Untargeted metabolomics experiments allow for the acquisition of
thousands of metabolite signals in a single sample [4]. However, a large percentage of these signals
remain structurally unknown [5], and therefore compound identification remains one of the large
obstacles in metabolomics [6,7].
Currently, two major analytical platforms are used in the small molecule identification process.
Nuclear magnetic resonance (NMR) is a powerful structure elucidation technique and it has
a significant advantage due to its nondestructive and noninvasive characteristics of analysis. However,
this method lacks the sensitivity needed for the simultaneous analysis of thousands of metabolites
observed in biological samples [8,9]. High resolution chromatographic separation techniques coupled
to accurate tandem mass spectrometry (LC-MS/MS) represents the most important metabolomics
platform. This technology allows for the physical separation of thousands of metabolites and therefore
provides a more comprehensive view of the metabolome.
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Classical structure elucidation using NMR commonly elucidates the full structure using de-novo
approaches [10]. The natural product [11], environmental [12] and mass spectrometry community [13]
usually have different definitions for compound identification. In metabolomics, five different levels
exist (see Table 1) including the new ‘Level 0’ that requires the full 3D structure and stereochemistry
information. More common are ‘Level 1’ annotations that are confirmed by two orthogonal parameters,
such as retention time and MS/MS spectrum. These levels were initially forged by the Metabolomics
Standards Initiative (MSI) of the Metabolomics Society [14,15] and were later refined by the compound
identification workgroup of the society. It is recommended to integrate the level of annotation for each
compound into metabolomic profiling reports.
Table 1. New confidence levels of compound annotations, as discussed by the Compound Identification
work group of the Metabolomics Society at the 2017 annual meeting of the Metabolomics Society
(Brisbane, Australia). The new addition refers to the ‘Level 0’ annotation; other levels remain as
discussed by the Metabolomics Standards Initiative.
Confidence Level Description Minimum Data Requirements
Level 0 Unambigous 3D structure: Isolated,pure compound, including full stereochemistry
Following natural product guidelines,
determination of 3D structure
Level 1 Confident 2D structure: uses reference standardmatch or full 2D structure elucidation
At least two orthogonal techniques defining 2D
structure confidently, such as MS/MS and RT or CCS
Level 2 Probable structure: matched to literature dataor databases by diagnostic evidence
At least two orthogonal pieces of information,
including evidence that excludes all other candidates
Level 3
Possible structure or class: Most likely
structure, isomers possible, substance class or
substructure match
One or several candidates possible, requires at least
one piece of information supporting the
proposed candidate
Level 4 Unkown feature of insterest: Presence in sample
A number of reviews have been published that cover many diverse metabolomics topics including
chromatography, data processing and statistics in great detail [16–24]. We mostly focus on papers that
discuss structure elucidation approaches involving liquid chromatography tandem mass spectrometry
(LC-MS/MS) within the last 5–10 years. The review is thematically divided into important sections that
include mass spectral database search, in silico fragmentation tools and orthogonal coupled techniques
including retention time matching and ion mobility spectrometry (see Figure 1). Lipidomics and
mass spectral imaging approaches are not fully covered. Classical chemical derivatization and isotope
labeling studies are discussed elsewhere [25]. Here, we only discuss a selected number of software
tools and databases than can help practitioners to obtain results during the annotation of unknown
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Figure 1. Computational metabolomics approaches help to unravel the complexity of the metabolome
and especially shed light on unknown metabolites. This includes technologies across different
disciplines, including quantum chemistry, machine learning, heuristic approaches and reaction
chemistry-based methods.
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2. Compound Databases and Chemical Space
The chemical space of small molecules currently covered in databases such as PubChem,
ChemSpider or the Chemical Abstracts Database is larger than 120 million compounds [16] (see Table 2).
The number of compounds with biological relevance is estimated at 1–2 million [27]. However, a large
majority of metabolites discovered during untargeted metabolic profiling remains unknown, including
many microbial [28], environmental [29] and natural compounds. In fact, very few reports in published
research have more than 20% identified compounds in untargeted analysis, as can be seen at the
Metabolomics Workbench [30], or the European metabolomics repository MetaboLights [31].
Table 2. Overview of selected compound databases commonly used for compound identification.
Database Targets Description
PubChem [32] All small molecules Small molecules, metadata
ChemSpider [33] All small molecules Small molecules, curated data
KEGG [34] Metabolites Pathway database, multiple species
MetaCyc [35] Metabolites Pathway database, multiple species
BRENDA [36] Enzymes Enzyme and metabolism data
HMDB [37] Metabolites Human metabolites
CHEBI [38] Small molecules Molecules of biological interest
UNPD [39] Metabolites Secondary plant metabolites
MINE [40] Metabolites In silico predicted metabolites
During the structure elucidation process, small molecule databases serve as a foundation of
known and well-researched metabolites (see Table 2). Enzyme and pathway databases such as KEGG,
MetaCyc and BRENDA serve as connectors to the proteomics and transcriptomics domain. Molecular
formulas or accurate masses can be queried in such databases, and potential structure candidates can
be retrieved to be investigated by in-silico fragmentation software tools. In many cases, it is important
to restrict the search space by including taxonomy information. Molecular discovery in humans can be
obtained from the Human Metabolome Database (HMDB) [37], and plant researchers should restrict
their search space to primary and secondary plant metabolites such as found in the UNPD (Universal
Natural Product Database) database [39] or compounds covered in the natural product space [41,42].
For exposome related research, environmental database resources can be utilized [43,44].
In case the compounds have not yet been described in the literature, enzymatic expansion
databases such as MINES (Metabolic in silico Network Expansion Databases) can be searched
(http://minedatabase.mcs.anl.gov/). MINES covers over 500,000 substances derived from KEGG
and other pathway databases by applying known enzymatic transformation rules [40]. These novel
compounds are not covered in traditional databases such as PubChem but can be utilized as
hypothesized starting molecules for structure elucidation [45].
3. Mass Spectral Database Search for Fast Annotations
Mass spectral database search is currently the fastest and most accurate way for initial compound
annotations. Current public and commercial mass spectral databases contain around 1–2 million
spectra of one million unique compounds. Most of these spectra are EI mass spectra for GC-MS,
while fewer are available for LC-MS/MS analysis. Traditionally, these databases have been derived
from authentic experimental reference compounds and were collected from the literature [46].
Lately, computationally generated in silico spectra have also gained in importance, as discussed
below. The experimentally derived as well as the in silico generated databases are enriched with
metadata such as instrument types, collision energies, ionization mode and structural information such
as the InChIKey [47] and SPLASH (spectral hash code) for uniqueness calculations [48]. Both InChIKey
and SPLASH are important as unique identifiers in the structural and spectral domain. Errors during
reference library building can be curated using software or manual data correction [49]. Table 3 lists
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a selection of commonly used mass spectral databases, see recent reviews for a complete coverage of
mass spectral databases [19,50].
Table 3. Overview of selected mass spectral databases commonly used for compound annotations.
Specialized reviews that cover other mass spectral databases are referenced in the text.
Database Targets Description
NIST EI-MS, CID-MS/MS Curated DB, graphical interface
WILEY EI-MS, CID-MS/MS Largest collection of EI-MS data
METLIN [51] CID-MS/MS Developed for QTOF instruments
MoNA EI, MS/MS, MSn Autocurated collection of spectra
MassBank [52] EI, MS/MS, MSn Longest standing community database
mzCloud [53] MSn Multiple stage MSn
GNPS [54] MS/MS Community database
ReSpect [55] MS/MS, RT Plant metabolomics database
In terms of coverage, up to 400 metabolites were identified from NIST plasma reference standards
utilizing multiple platforms and database matching [56]. The NIH Common Fund metabolomics ring
trial with the participation of multiple US labs annotated around 1000 metabolites using multiple
technologies and reference spectra matching. However, literature references for the plasma or serum
metabolome covered up to 5000 compounds by combining targeted and non-targeted metabolomics
analysis from five platforms [57]. It is therefore clear that matching experimental reference spectra
to experimental reference databases is a severely limited process and covers only a fraction of the
detectable metabolome.
Many modern algorithms for peak detection and mass spectral deconvolution have in-built
database search algorithms. That includes freely available search algorithms such as the NIST MS
Search GUI (graphical user interface), NIST MS PepSearch or MS-DIAL [58]. Commercial software
from mass spectrometry vendors use similar algorithms.
Scoring mass spectra has been traditionally performed by a number of algorithms
such as probability match searching, dot-product search and other similarity measures [19].
Recently, a novel hybrid similarity search method has been introduced that can annotate unknown
spectra. The method does not account for the precursor m/z and instead utilizes similar neutral
losses and fragmentation patterns [59]. Spectral similarity can also indicate structural similarity and
this information can be used for annotation of unknown compounds [60]. Clustering approaches
that use the cosine similarity of product ion spectra by clustering structurally similar compounds
can improve the annotation of unknown metabolites [61]. Despite the advantages of a fast library
search, it is becoming clear that mass spectral scoring algorithms have to be improved, especially for
product ion spectra that contain only few fragments [46] or for those libraries that integrate spectra
from multiple instrumentation types. Here, approaches that can calculate false discovery rates (FDR)
will be useful to improve spectral match and annotation quality [62,63].
Community efforts have positively impacted the sharing of mass spectra. The MassBank database
(http://massbank.jp) is one of the most successful examples, with a wide user base and contributors
from many different countries [52]. In a coalition of database servers, the European MassBank
efforts (https://massbank.eu/) [64] and MassBank of North America (http://massbank.us/) enable
immediate sharing of mass spectra of annotated structures, including autocuration of spectra and
chemical structure information (InChI keys). In comparison, the GNPS [54] spectral database utilizes
crowd sourcing approaches to annotate unknown compounds. Commercial libraries such as NIST17
still play an important role because of high levels of manual curation, overall good data quality and
wide coverage of substances.
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4. In Silico Generation of Mass Spectra and MS/MS Spectra
As described before, scientists today have access to around 100 million known compounds in
PubChem and ChemSpider. However, fewer than one million compounds have associated electron
ionization (EI) mass spectra (for GC-MS applications), and even fewer LC-MS/MS tandem mass
spectra are available. Generating in silico mass spectra, therefore, is a unique opportunity to close this
gap. Research into computational generation of mass spectra has gained much traction during the
last five years. Four general methods can be distinguished: quantum chemistry, machine learning,
heuristic-based methods and chemical reaction-based methods.
Quantum chemistry methods use first-principles and purely physical and chemical information
to generate mass spectra. In a major breakthrough for computational mass spectrometry, Grimme
described in 2013 how Born–Oppenheimer ab initio molecular dynamics can be used to generate in
silico electron ionization mass spectra of any given compound [65–69]. An overview of methods for
in silico generation of mass spectra, including commercially or freely available algorithms is listed
in Table 4.
Table 4. Overview of methods for in silico generation of mass spectra, including commercially or freely
available algorithms. Additional tools are referenced in text.
In Silico Method Software Platform Description




Requires diverse training sets;
Fast method
Heuristic approaches LipidBlast CID-MS/MS for specific compound classes(lipids); Fast method
Reaction chemistry methods MassFrontier EI-MSCID-MS/MS
generates only bar code spectra;
Covers experimental gas
phase reactions
Machine learning-based methods such as CFM-ID developed by Allen et al. allow for
the computation of CID-MS/MS [70] and EI-MS spectra [71] directly from molecular structures.
It is a very versatile approach useful for small molecules and peptides up to 1000 Da [72].
The methodology requires diverse and large training sets which subsequently will improve overall
accuracy during training.
Heuristic approaches such as LipidBlast are advantageous for compound classes that have
reoccurring and predictive fragmentations such as lipids [73]. However, the heuristic approach cannot
be expanded to molecules with very diverse structural scaffolds. The libraries themselves can be easily
extended to include novel or recently discovered lipid classes [40,45,74].
Reaction-based approaches are covered in the Mass Frontier software (HighChem Ltd., Bratislava,
Slovakia) and based on thousands of reactions discovered in the literature. Novel molecules can be
fragmented based on observed reaction pathways. Only bar code spectra can be generated, hence peak
abundances are missing.
The accuracy of in silico generated peaks and their abundances have to be largely improved.
A comparison between QCEIMS and CFM-ID has shown that both algorithms perform well enough to
get correct identifications for half of the 61 investigated molecules [75]. However, certain rearrangement
reactions, including McLafferty rearrangements, remain underestimated. The highly accurate and fast
OM2 and OM3 semiempirical methods [76] have been further improved by the GFN-xTB Hamiltonian
into QCEIMS [77]. Independent approaches described DFT reaction pathway and transition state
modelling to model EI mass spectra [78] or Monte Carlo sampling to obtain EI mass spectra for
select cases [79].
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Currently, there is no fully automatic software for the generation of in silico MS/MS spectra based
on LC-MS collision induced dissociation (CID). Several groups have shown interest in this challenging
topic and have provided steps that can finally lead to a fully automated stand-alone solution.
That includes workflows to automatically find the correct protonation sites in a molecule [80,81],
ways to utilize rotamers, conformers, Boltzmann averaging and the evaluation of semiempirical and
density functional methods (DFT) to calculate fragments.
The validation of generated in silico spectra is probably the most crucial aspect, especially when
‘blindly’ applying software models to large molecule repositories. For example, the original CFM-ID
models were trained on a number of small metabolites. Therefore, these initial models are focused on
lower molecular weight molecules and may not be feasible for the generation of in silico spectra of
high molecular weight lipids or large complex secondary metabolites. In order to obtain high accuracy,
the CFM-ID models have to be retrained with adequate lipid and secondary metabolite training sets.
As always, external validation with mass spectra that were not available during training is highly
recommended. For ab initio models, large validation sets with thousands of compounds have to be
generated to obtain confidence scores.
Furthermore, regarding in silico spectra, two major problems will arise in the future.
First, calculational processes follow the normal distribution; hence a large number of average accuracy
in silico spectra will be observed. The flanks will consist of a small number of inaccurate spectra as
well as a small number of high-quality spectra. Here, research needs to focus on ways to improve
the average accuracy of in silico spectra predictions, but also to exclude such low-quality in silico
spectra. In addition, the community will need to develop improved MS/MS match confidence
scores. Otherwise, wrong spectra and publications with false compound annotations lead to many
false-positive annotations in databases. The second problem is the generation of millions of very similar
in silico spectra, because compound databases host millions of structurally very similar compounds.
This will lead to an effect called database poisoning, filling mass spectral databases with compound
spectra that cannot be easily distinguished by database search alone. Here, research has to focus on
orthogonal filtering methods such as ion mobility or retention time filters.
5. In Silico Fragmentation Software
In silico fragmentation approaches for the annotation of unknown molecules are used in those
cases where no reference mass spectra are available for database matching [82]. These generally
involve matching experimental spectra against a selection of in silico generated fragments calculated
on candidates retrieved from known compound databases (see Figure 2). Instead of searching mass
spectral databases which cover only one million compounds, in silico fragmentation algorithms
have access to molecular structure databases including ChemSpider and PubChem covering almost
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Figure 2. In silico fragmentatio t ols such as MS-Finder, CFM-ID, CSI:Fi gerID nd Metfrag
utilized known compounds from structure databases to calculate fragments compare those theoretical
fragmentations against experimental spectra. When combined with MS/MS database search and
utilizing additional metadata annotation rates can be increased tremendously.
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These in silico fragmentation approaches aim to identify “known unknowns”—i.e., compounds
present in molecular structure databases but without any reference spectra—by calculating a score
between the experimental spectra and the predicted spectra (or predicted fragments). The major
disadvantage is that “unknown–unknown” compounds cannot be elucidated in such a way.
Below, we discuss some of the tools that have participated in structure elucidation challenges and can
be used for batch annotations of unknown compounds (see Table 5). Additional software including
iMet [84], MAGMa [85], MIDAS [86] and Midas-G [87] are discussed elsewhere. Most of the approaches
below have been discussed in much greater technical detail in a series of excellent reviews [88–91].
Table 5. Selection of in silico fragmentation software, including commercially or freely available
algorithms. Additional algorithms are referenced in the text.
Tools Fragmentation Method Compound DB Type of Interfacce
MS-FINDER Rule-based(hydrogen rearrangement rules)
15 integrated target DBs plus
MINE and PubChem Windows GUI
CFM-ID Hybrid rule-basedmachine learning KEGG, HMDB
Web application and
command line tool
MetFrag Hybrid rule-basedcombinatorial HMDB, KEGG, PubChem
Web application,
command line tool,
Mass Frontier Rule-based(literature reaction mechanisms) Internal MS database Windows GUI
ChemDistiller Fingerprint and spectralmachine learning
17 different target databases,
130 Mio compounds total
Command line,
web-based output
MAGMa, MAGMa+ Rule-based PubChem, KEGG, HMDB Web application,command line tool





MetFrag [92] is a combinatorial fragmenter that retrieves candidate structures from PubChem,
ChemSpider, KEGG, and a few other more specific compound databases. Candidates are fragmented
using a bond dissociation approach and are finally matched to experimentally obtained spectra.
MetFrag and MetFusion [93] have been actively developed and improved, allowing local or web-based
use. The LipidFrag tool was developed later to increase confidence in lipid annotations [94].
MS-FINDER [84] is a Windows based GUI software aiding the structure elucidation process by
in silico fragmentation of all predicted molecular formulas, determined from the accurate mass,
isotope ratio, and product ion information [95], which are retrieved from 15 databases that are
embedded into MS-FINDER [96,97]. The structures are then ranked by variety of factors including
nine hydrogen rearrangement rules as the most contributing factor to the final score calculations.
CSI:FingerID [98] is a freely available web-service and uses a two-step scheme: first, a kernel-based
approach is utilized to predict molecular fingerprints [99] from its MS/MS spectrum and then the
predicted molecular fingerprints are matched against a molecular compound database. Included is
a module that combines computation and comparison of fragmentation trees for the prediction of
molecular properties of the unknowns as well as the molecular formula generation. Novel algorithms
such as IOKR (input output kernel regression) [100] are now integrated into the workflow.
The stand-alone SIRIUS GUI software [101] is used to calculate fragmentation trees and, subsequently,
molecular formulas [102]. SIRIUS is now directly coupled to the CSI:FingerID online server that
matches fingerprints against a database and retrieves ranked structure candidates.
CFM-ID (competitive fragmentation modeling) is a suite of software tools that can perform
spectra prediction and compound identification. It is based on a machine-learning approach including
chemical rules andva is available for ESI MS/MS data as well as EI mass spectra. CFM-ID can be used
as a web server or can be called locally through command line utilities on Windows, Linux and MacOS.
For larger datasets, the software can be deployed to clusters to reduce the computational times.
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ChemDistiller [103] is a Python-based tool that uses structural fingerprints and fragmentation
patterns together with a machine learning algorithm to annotate unknown compounds. It utilizes
multiple target databases covering more than 130 million compounds to annotate unknowns and the
output is presented in a web interface for further inspection. It is a very fast and highly parallelized
tool that makes use of modern multi-core CPUs.
Mass Frontier [82], developed by HighChem, is based on observed experimental gas-phase
fragmentation reactions. It contains basic fragmentation rules as well as an exhaustive library of over
100,000 known fragmentation rules collected from published data which also allows for fragmentation
predictions and annotation of unknowns [104]. The software supports electron ionization (EI) and
collision induced dissociation (CID) ESI MS/MS modes. Mass Frontier can search internal databases
or the mzCloud database and is commercially available.
To improve the annotation rates, database type restrictions such as environmental, plant,
metabolic pathway databases can be applied. Taxonomy restrictions are also useful when researching
specific organisms. Generally, in silico fragmentation algorithms still need to improve tremendously.
A comparison of four algorithms using the CASMI test compounds as input has shown that pure in
silico algorithms could only identify 17–25% of the compounds correctly [105]. Boosting the output by
adding MS/MS search and bio-database focused lookups as well as combining the outputs of multiple
software tools led to much higher identification rates of up to 93% accuracy [106]. Combining multiple
in silico fragmentation software with a-priori information is a valuable option when facing a structure
elucidation challenge [106].
6. Retention Time Prediction
Retention times are important as orthogonal filters during the structural determination in
metabolic profiling experiments. A number of MS/MS and retention time databases have
been developed for metabolic profiling [55]. However, these tools usually contain only a few
hundred experimentally obtained retention time values. It is therefore useful to predict theoretical
retention times utilizing the millions of existing compounds in compound databases by quantitative
structure-retention relationship (QSRR) modelling [107]. This field of research has been active for more
than 30 years. Traditionally, group-contribution methods were used for GC-MS modelling by assigning
small retention index increments to specific substructures [108]. However, a vast amount of different
separation columns and an infinite combination of solvent buffer systems and chromatographic
conditions exist in LC-MS, locking the predicted models to very specific conditions [109].
Another major reason why there is no universal retention prediction method for LC-MS/MS
is the lack of large and diverse training sets. A minimum of a thousand compounds covering all
major chemical scaffolds in hydrophilic interaction liquid chromatography (HILIC) or reversed-phase
chromatography (RP) are required to generate a robust retention prediction model useful for
metabolic profiling.
An additional important consideration for retention time models is the applicability domain
or structural space used in model building [110]. In short, if a natural product training set is used,
it should be used for the prediction of natural product predictions and not for drugs. A simple measure
would be to perform a principal component analysis on the substructure feature space for training
samples and new predictive compounds and to confirm that the space overlaps. However, a recent
approach utilized 1955 synthetic screening compounds that cover a similar scaffold space as small
metabolites and used artificial neural networks to predict LC-MS retention indices for 202 endogenous
metabolites [111]. This approach is particularly interesting because plated screening compounds are
commonly less expensive than endogenous metabolites. By massively increasing the structural scaffold
space, the retention model can become more robust, even if these molecules will never be annotated in
biological samples. Many retention time prediction models are usually locked to a specific LC column
and a solvent and buffer system, unless a “retention projection” method can be applied to transfer
data to other chromatographic systems [112–114].
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Retention times can be predicted by using chemical descriptors as input parameters which can
be computed directly from structures by tools such as Dragon [115], MOLD2 [116] or PaDel [117].
Dragon 7 now calculates 5270 molecular descriptors, covering fragment counts, topological and
geometrical descriptors. Low-energy three dimensional conformer structures can be generated
by a number of tools [118] and even better with quantum chemical methods [119]. Subsequently,
regression models can be built using the descriptor data as input and the retention time as a target
function. Over 200 machine learning models, preferably with deep neural networks [120] or fast
random forest methods [121], are now available. To improve accuracy and prediction power,
complex gradient boosting methods (XGBoost/LightGBM) and ensemble methods such as bagging,
stacking and averaging are now routinely employed [122]. In the past, a wide variety of retention
prediction models have been proposed for HILIC and reversed phase columns based on different
machine learning approaches. These included partial least square methods [123–125], multiple
linear regression [126–128], support vector regression [129,130], random forests [131] and artificial
neural networks [132–134].
In summary, the success of the retention time modelling depends on the size and the diversity
of the compound training data set. Currently, most RT models are locked to specific columns and
conditions, unless a retention projection method is used. For useful retention time prediction models,
the only remedies are large and diverse training sets covering multiple compound classes to obtain
reliable, highly predictive and accurate models.
7. Ion Mobility and the Use of Collision Cross Section (CCS) Values
LC-MS/MS alone will often be unable to discriminate between stereoisomers and regioisomers,
unless chiral columns are utilized. It is therefore useful to couple ion mobility analyzers to LC-MS/MS
to allow for a higher number of features to be separated and detected [135]. Ion mobility is a technique
that separates ions in an inert buffer gas (nitrogen, hydrogen) under the influence of an electric
field [136,137]. Several types of ion mobility analyzers are available, among them drift tube ion
mobility (DTIMS), traveling wave ion mobility spectrometry (TWIMS) and FAIMS [138].
For DTIMS and TWIMS, the observed drift times are influenced by relative molecule size
and conformational parameters. For DTIMS, cross-section values (CCS) can be directly measured
and computed [139,140], and for TWIMS the CSS values can be obtained from calibrations with
known standards [141]. The FAIMS technology has limited peak capacity [142,143], but can
be used as an orthogonal filter to separate different classes of compounds and to improve
signal/noise ratios during measurements [144]. For FAIMS, no collision cross-section values (CCS)
can be determined [138].
The experimental CCS values have a very high reproducibility and CCS values with relative
standard deviation (RSD) of <1–2% can be routinely obtained [139,145,146]. This opens up
the LC-IMS-MS/MS technology for orthogonal filtering approaches utilizing CSS values [147]
(see Figure 3) and more importantly for predictive technologies utilizing CCS values in a similar
to retention time predictions. Such predictive approaches can include computational and quantum
chemical models [148,149] as well as machine learning predictions [150] such as artificial neural
networks [132,151]. Prediction errors as low as 3% have been reported for CCS models [152]. Once these
models are applied to structures from large metabolomic databases, they can be used for filtering
during the compound identification process [138,153], and such predicted values are covered in
publicly available databases such as MetCCS [152] or LipidCCS [154,155]. Currently, an estimated total
of 3000–4000 experimental small molecule CCS values have been reported in a recent review [150]
with the largest single collection containing CCS values for 1420 compounds [145]. Focused collections
for sterols [156], metabolites and xenobiotics are also available [139,157].
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Several considerations have to be taken into account when working with CCS values and
predictive databases. CCS values of individual compounds depend on many additional parameters
such as buffer gas, solvents, temperature, pH, ion activation voltage and conformer/rotamer
ensembles [158,159]. For example, different ion species such as [M + H]+ and [M + Na]+ have
different CCS values, differing on average ±7 Å2 based on values obtained from [139]. This is related
to conformational changes and subsequently leads to the conclusion that different adducts have to be
modelled and predicted separately. Furthermore, different protonation sites or protomers can lead to
different CCS values [145]. Drugs such as benzocaine can have N- or O-protonated forms leading to
different CCS values for the same compound [160]. The different protomers can be determined with
the help of quantum chemical methods [161,162] and cheminformatics methods that calculate different
protonation sites. Reference standards themselves may not be enantiomerically pure and therefore can
lead to measurement of multiple experimental CCS values. Furthermore, while CCS values predicted
on the same instrument type have low RSD measurement errors <1% [163], the experimental CCS
values may differ between different instrumental setups (DTIMS/TWIMS), as well as prediction
models. The drug Indomethacin for the proton adduct has a reported CCS value of 183.54 Å2 measured
on a drift tube IMS (DTIMS) [139]; the same compound has a CCS value of 179.039 Å2 measured
on a TWIMS setup, and the predicted value is 197.7 Å2 and therefore falls outside the 3% median
prediction error [164].
Because of the IMS capability of separating stereoisomers and other isobaric compounds,
the routine use of CCS values will become more and more important. The excellent experimental
reproducibilities of CCS measurements compared to retention times will also improve identification
rates. Once larger CCS datasets become publicly available, they can be combined, average consensus
values can be calculated and CCS prediction methods can be retrained with larger compound numbers
and therefore will automatically become more accurate. Technological advances such as printed
circuit board (PCB)-based devices led to ion elevators and escalators in multilevel structures [165].
Therefore, such structures for lossless ion manipulations (SLIM) have demonstrated unprecedented
ultra-high resolution ion mobility [166].
8. Compound Identification: Hybrid and Orthogonal Approaches
The following section discusses some general compound identification workflows as well as a few
selected cases of single compound identification examples via mass spectrometry. Workflows are
important for highly reproducible and repeatable metabolomics analysis. Among those are Galaxy
workflows [161] such as Workflow4metabolomics.org, as well as Taverna and KNIME workflows,
but with a considerably lower user base [167]. A conceptual compound ID workflow has been
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described that includes in silico metabolic synthesis, in silico fragmentation [168] and finally annotation
of compounds via database scoring [169]. The same paper discusses the importance of meta-integration
of multiple tools and multiple layers of information to improve confidence in compound identification.
Another related review discusses the importance of inclusion of MS1 peak relationships such as adducts
and neutral losses, the inclusion of MS/MS data and biochemical knowledge as well as modelling of
retention times as an orthogonal filter. A knowledge-based workflow for metabolite annotations that
includes ionization rules, adduct formation rules and retention time rules was described in [170].
However, even in-source fragmentation LC-MS mass spectra when used together with retention
times of authentic compounds can be sufficient for ‘Level 1’ annotations in metabolomics [171].
A pipeline that uses multicriteria scoring, including retention times, intensity profiles and
adduct patterns was developed for high-resolution mass spectral data [172]. The extraction of
common occurring substructures from MS/MS data can help during higher level annotations [173].
Another workflow included the use of multiple identification criteria such as accurate mass,
retention time, MS/MS spectrum, and product/precursor ion intensity ratios to support reversed
phase and HILIC based metabolic profiling [174]. Two in silico fragmenters and two retention
prediction models were utilized to annotate hydrophobic compounds [175]. A tool for improved
and automated adduct detection was discussed in [176], leading to 83% correct annotations of adduct
ions. The dereplication of natural products with the help of a fragment database was described in [177].
Pitfalls, limitations and general recommendation during data processing and compound identifications
were discussed in [24,178,179].
Full structure elucidation of single novel compounds with chromatography and mass
spectrometric analysis is possible but is harder than with the isolation of compounds and NMR
analysis. A clear benefit of LC-MS/MS approaches is the limited amount of material needed,
in comparison to LC-MS/MS-NMR methods. A recent report annotated N1-acetylisoputreanine and
N1-acetylisoputreanine-gamma-lactam by metabolic profiling and used custom synthesis to confirm
the commercially unavailable metabolite [180]. Another approach used multiple-stage tandem mass
spectrometry (MS4) and custom synthesis to identify and confirm N,N,N-trimethyl-l-alanyl-l-proline
betaine in human plasma. Novel glycolipids were found in yeast annotated by combining multiple
mass spectrometric platforms and chiral chromatography to ascertain stereoisomer configuration [181].
Another approach showed the combined use of high-resolution MS/MS data and use of the metabolic
in-silico network expansion database (MINE) for the discovery of novel methylated epi-metabolites
including N-methyl-UMP [45]. Natural products can be manually annotated with high success
rates [182], but such approaches require deep mass spectral knowledge. In the future, such manual
approaches must be translated into practical expert-algorithms and software that allows non-experts
to perform such complicated analysis to a certain degree [27]. Finally, all pipelines and workflows
must be validated by independent and external benchmark sets such as the CASMI competitions
discussed below.
9. Critical Assessment of Small Molecule Analysis (CASMI)
The CASMI (critical assessment of small molecule identification) contest (http://www.casmi-
contest.org) has been held since 2012 as a worldwide scientific competition to determine the
best approaches for identifying small molecule structures directly from mass spectra [183,184].
The competitions are commonly structured into different categories, including best natural product
determination [96,182,185], best molecular formula determination [186] and unknown compound
determination. More recently, categories that allow for in silico fragmentation software only [187]
and a category that allows for all meta-data use were included [85]. Participants publish their findings
in special journal issues selected by the CASMI organizers and describe how they implemented and
performed their structure annotation processes.
The latest CASMI 2017 contest featured 300 small molecule challenges and may continue to serve
as a test bed for the performance and comparison of software tools and pipelines. On the other hand,
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many research papers describe approaches and pipelines that focus on a few selected “cherry picked”
test cases. Therefore, it is recommended for groups that develop compound identification software to
participate in the yearly CASMI contests to showcase the performance of their software against others.
Best of all, any published article about novel approaches or software tools should participate in the
CASMI small molecule identification contests or at least use former CASMI data sets for validation of
the approaches used.
Future CASMI contests may be held in a completely automatic fashion, as long as the software
and pipeline are fully publicly available. One idea would be to make these tools so easy to use
that non-specialists from the broader community can utilize them quickly and improve compound
identification rates. The increasing number of challenges and CASMI participants shows that the field
of unknown-identification is moving steadily forward.
10. Data Sharing and Data Retention
Sharing research data and software helps to validate the claims made in publications and,
more importantly, lets researchers freely reuse that data and develop novel research ideas [188].
Unfortunately, while journals support data sharing, they often do not strictly enforce it [189].
Here, funding agencies such as the National Institutes of Health (NIH) in the United States have
a large leverage to make data sharing mandatory. Both NIH and the US National Science Foundation
(NSF) require data retention and data sharing plans for grant proposals, cultivating a way for better
reuse of research data. Currently, funding organizations worldwide do not strictly enforce the public
sharing of metabolomics data. This is contrary to genomics, where deposition of genomic data is
required before any publication.
For computational tools and software, it is recommended to use public software repositories
such as GitHub, BitBucket and SourceForge services (see Table 6). In this case, repositories can be
forked (copied) and multiple copies remain even when the original distributer does not support
them anymore.
Table 6. Overview of collaborative software and data sharing repositories, major metabolomics
repositories and mass spectral sharing initiatives.
Data Sharing Link Description
GitHub github.com Software development platform
BitBucket bitbucket.org Collaborative software sharing
SourceForge sourceforge.net Collaborative software sharing
Zenodo zenodo.org Open research data repository
Figshare figshare.com Online research data repository
Metabolomics Workbench metabolomicsworkbench.org Experimental metabolomics data
MetaboLights ebi.ac.uk/metabolights European metabolomics repository
OpenMSI openmsi.nersc.gov Mass spectral imaging data
MetaSpace metaspace2020.eu Mass spectral imaging data
GNPS gnps.ucsd.edu Mass spectral data sharing
MassBank massbank.jp Mass spectral data sharing
MoNA massbank.us Mass spectral sharing community
Norman MassBank massbank.eu Mass spectral data sharing
For metabolomics data sets, the Metabolomics Workbench [30] or the European metabolomics
repository MetaboLights [31] should be considered. These repositories contain a high level of metadata
information, which requires a high level of data preparation before the upload process. The advantage
is that experiments are very well described and that such metadata can be queried at a later time
point. The incentive of the GNPS repository [54] is that mass spectra of many unknown compounds
are collected, and identification of such spectra might be enhanced through community efforts.
The OpenMSI [190] and Metaspace.eu [63] projects provide open analysis solutions for mass spectral
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imaging data. Scientific data sets from all branches of research can be submitted to the Zenodo research
repository, which also supports citable digital object identifiers (DOI). The long-standing effort of
collecting freely available mass spectra of pure reference compounds at MassBank (Japan) has now
been complemented by collaborative efforts in the USA (MassBank of North America, MoNA) and the
Norman MassBank in Europe. Due to the allowed unrestricted use, open spectral collections can be
used for algorithm training in open or commercial software.
Specifically, the MoNA database has an advantage of automated spectral uploads via REST API,
which allows for instantaneous sharing of novel compounds and associated spectra. MoNA collates
all worldwide publicly available mass spectra, including spectra from MetaboBASE, GNPS, HMDB,
LipidBlast, ReSpect and MassBank spectra in one unique repository. Users can freely download
spectra based on metadata tags, including based on instrument, vendor, mass accuracy, types of
chromatography, or based on compound classes (supported by ClassyFire) [191].
The publication of tools or databases that are neither publicly nor commercially available should
be avoided. Such opaque software does not contribute much to the field and cannot be validated
independently. We therefore mostly refrained from referencing such publications or tools in this review.
Software tools should be validated on public, large and diverse datasets before making claims that
they outperform any other tool.
11. Conclusions and Outlook
Computational metabolomics strategies for compound identification have gained increased
attention in the community. Unknown metabolite signals cannot easily be used for biological
interpretations [7], and increased efforts and validations for compound identifications are critical
for the field to move forward. Approaches that do not require the identification of metabolic features
should be used with extreme caution because they may lead to false interpretations. The identification
of metabolites with a high level of confidence is required in order to improve metabolomics applications
in the field of translational and clinical research.
Bioinformatics researchers have helped the proteomics and genomics community over many
years to solve problems in their domain. However, the bioinformatics community had a smaller impact
on the small-molecule community due to the chemical structure-centric approaches that are needed
for structure elucidation in metabolomics. To this end, the much smaller cheminformatics community
still struggles to provide adequate support simply due to its much smaller size and impact. Therefore,
collaboration with researchers from scientific branches such as machine learning and the quantum
chemistry community need to be actively embraced. The computational metabolomics community is
a quite small but innovative community, and many more research groups worldwide contribute now
in friendly competition.
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Abbreviations and Glossary
MSn Multiple stage mass spectrometry
CASMI Critical Assessment of Small Molecule Identification
CCS Collisional cross-section
CFM-ID Competitive Fragmentation Modeling for Metabolite Identification
FAHFAs Fatty Acid ester of Hydroxyl Fatty Acids
Fragmentation tree Mass spectral fragmentation pathway of a compound
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GNPS Global Natural Products Social molecular networking
HMDB Human Metabolome Database
IM Ion mobility
InChIKey Hash key or short unique structure code
LipidBlast In silico generated database for lipid identification
MassBank Mass spectral database
MetaboBASE Mass spectral library developed by Bruker
MoNA MassBank of North America
NIST National Institute of Standards and Technology
NMR Nuclear Magnetic Resonance
ReSpect RIKEN MSn spectral database for phytochemicals
SPLASH Hashed code or unique identifier for mass spectra
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